Anti-SARS-CoV-2 REGN-COV2

DB15691InvestigationalProtein Based Therapies

Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of... This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19.

Mechanism: Pharmacologically active on Spike glycoprotein
Curator reviewed
Also known as: REGN-COV2 · REGN10933+REGN10987 combination therapy

Resolves to

Targets

P0DTC2S

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anti-SARS-CoV-2 REGN-COV2, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account